ScoreWhy is Collegium Pharmaceutical, Inc. ?
1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55
- The company has been able to generate a Return on Capital Employed (avg) of 18.24% signifying low profitability per unit of total capital (equity and debt)
2
Healthy long term growth as Net Sales has grown by an annual rate of 19.71% and Operating profit at 33.13%
3
With a growth in Operating Profit of 20.94%, the company declared Very Positive results in Sep 25
- The company has declared positive results in Jan 70 after 2 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at USD 290.92 MM
- INTEREST COVERAGE RATIO(Q) Highest at 551.87
- RAW MATERIAL COST(Y) Fallen by -1.57% (YoY)
4
With ROCE of 18.04%, it has a fair valuation with a 1.98 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 18.85%, its profits have fallen by -42%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Collegium Pharmaceutical, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Collegium Pharmaceutical, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Collegium Pharmaceutical, Inc.
18.85%
0.16
39.04%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.71%
EBIT Growth (5y)
33.13%
EBIT to Interest (avg)
1.55
Debt to EBITDA (avg)
3.22
Net Debt to Equity (avg)
3.17
Sales to Capital Employed (avg)
0.60
Tax Ratio
32.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
18.24%
ROE (avg)
24.91%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
4.23
EV to EBIT
11.00
EV to EBITDA
4.60
EV to Capital Employed
1.98
EV to Sales
2.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.04%
ROE (Latest)
22.76%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 290.92 MM
INTEREST COVERAGE RATIO(Q)
Highest at 551.87
RAW MATERIAL COST(Y)
Fallen by -1.57% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 8.51 times
NET SALES(Q)
Highest at USD 209.36 MM
OPERATING PROFIT(Q)
Highest at USD 120.13 MM
PRE-TAX PROFIT(Q)
Highest at USD 44.97 MM
NET PROFIT(Q)
Highest at USD 32.62 MM
EPS(Q)
Highest at USD 0.84
-3What is not working for the Company
NET PROFIT(9M)
At USD 48.9 MM has Grown at -35.57%
Here's what is working for Collegium Pharmaceutical, Inc.
Interest Coverage Ratio
Highest at 551.87
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Pre-Tax Profit
At USD 44.97 MM has Grown at 121.98%
over average net sales of the previous four periods of USD 20.26 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 32.62 MM has Grown at 143.17%
over average net sales of the previous four periods of USD 13.41 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 290.92 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 209.36 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 209.36 MM has Grown at 18.45%
over average net sales of the previous four periods of USD 176.75 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 120.13 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 44.97 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 32.62 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.84
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 8.51 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -1.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
